Apixaban
Apixaban 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Atrial Fibrillation、Venous Thromboembolism (VTE)、Multiple Myeloma、Total Knee Replacement。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
10 项
已进入 III/IV 期
26 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- VA Office of Research and Development
- Regeneron Pharmaceuticals
- Centre Hospitalier Universitaire de Saint Etienne
- University of Birmingham
- Odense University Hospital
- Population Health Research Institute
- Seoul National University Hospital
- GUALTIERO PALARETI
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
英国、丹麦、澳大利亚、加拿大、德国、South Korea、意大利、Russia、Israel、Tunisia、美国、法国
正在招募患者的 Apixaban 研究
Preventing Stroke, Premature Death and Cognitive Decline in a Broader Community of Patients With Atrial Fibrillation
IV 期招募中英国NCT04700826Can Patients With Atrial Fibrillation Safely Discontinue Anticoagulant Therapy After Cardiac Surgery? (ATLAAC)
IV 期招募中丹麦NCT06401616The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery Trial
III 期招募中澳大利亚加拿大德国NCT04284839Pacing of Left Bundle Branch Area and Atroventricular Node ablatIon in Patients With Symptomatic Atrial Fibrillation
不适用招募中South KoreaNCT06699342START-Register: Survey on Anticoagulated Patients Register
不适用招募中意大利NCT02219984CLOT-LESS - CLOsure Tailored: LEss Antithrombotic Strategy After LAAC for Stroke Prevention
不适用招募中RussiaNCT07575867Prevention of Thromboembolism Using Apixaban vs Enoxaparin Following Spinal Cord Injury
不适用招募中IsraelNCT05484557Comparison of DOACs and LMWH for Thromboprophylaxis After Total Knee Arthroplasty
不适用招募中TunisiaNCT07869615Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
III 期招募中美国NCT03907046Efficacy of Prolonged Anticoagulation for Primary Prevention of Venous Thromboembolic Disease in Autoimmune Hemolytic Anemia: a Prospective, Phase II, Randomized, Multicenter Study
II 期招募中法国NCT05089227Registry of Patients Prescribed Anticoagulation
不适用招募中美国NCT03504007Clinical Performance Evaluation of Native Whole Blood Samples of Patients on DOACs With the Perosphere ClotChek™
不适用招募中美国NCT07012291Net Clinical Benefit of Edoxaban Versus Apixaban in Patients With Atrial Fibrillation and Coronary Artery Disease
IV 期招募中South KoreaNCT07753200Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD
不适用招募中中国NCT07461532Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation
III 期招募中芬兰Iceland挪威瑞典NCT05679024BEACON-AA: Apixaban With or Without Clopidogrel in Stroke Patients With Atrial Fibrillation and Cerebral Atherosclerosis
IV 期招募中South KoreaNCT07237308Single-stage Pulmonary Vein Isolation Combined With Percutaneous Left Atrial Appendage Occluder Implantation in Patients With Recent Onset Ischemic Stroke and Atrial Fibrillation
IV 期招募中PolandNCT06212674inDividual, Targeted thrombosIS Prophylaxis Versus the Standard 'One Size Fits All' Approach in Patients Undergoing Total hIp or Total kNee replaCemenT
IV 期招募中荷兰NCT06581965Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS
不适用招募中中国NCT07461545APIXABAN App Study
不适用招募中South KoreaNCT06903845Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies
不适用招募中PolandNCT07270263Apixaban in Thrombocytopenia
早期 I 期招募中美国NCT06886516Optimal Anti-Thrombotic Management Following Percutaneous Left Atrial Appendage Occlusion
III 期招募中美国NCT07840365Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants
不适用招募中奥地利比利时加拿大法国NCT06556446
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。